NASDAQ Soins de santé Biotechnologie AUPH

Aurinia Pharmaceuticals Inc.

$ 16.46 1.98 %

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

CEO: Kevin C. Tang - https://www.auriniapharma.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$12.6 -23.45 %

Recommandation

Buy

DCF

$ -49.08

Loading data...

AUPH vs S&P500

Loading data...

No data available.

Quick ratio

5.01

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

7.62

may indicate that the company is undervalued or has poor growth prospects.

EPS

2.16

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

64.48 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

18.99 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

10.82

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.12

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.25

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
8.65 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.47 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.09 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.